BIOGEN INC. (BIIB)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Address

225 BINNEY STREET
CAMBRIDGE, MA 02142

Founded

1978

Number of Employees

7,570

Website

http://www.biogen.com

Buyback

Buyback Data 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Average
$ Amount Purchased
($ in 000s )		 $526,799 $5,000,025 $999,990 $781,789 $4,352,630 $4,958,355 $6,679,081 $1,800,014 $750,003 - - $2,872,076
Average Price $312.91 $298.23 $300.57 $272.23 $293.34 $252.24 $298.07 $298.61 $208.04 - - $283.48
# Shares Purchased 1,683,575 16,765,815 3,327,022 2,871,804 14,838,271 19,657,265 22,407,421 6,027,962 3,605,076 - - 10,131,579
Buyback Performance 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Average
Total Return to Date -37.7% -34.6% -35.1% -28.4% -33.5% -22.7% -34.6% -34.7% -6.3% - - -31.2%
S&P 500 Return to Date 181.9% 173.0% 168.6% 129.7% 104.9% 93.1% 74.8% 31.7% 37.3% - - 110.5%
Excess Total Return -219.5% -207.6% -203.7% -158.1% -138.4% -115.8% -109.4% -66.3% -43.5% - - -141.8%
Quartile Rank
Percentile Rank 21% 21% 19% 24% 19% 22% 13% 21% 40% - - 23%
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.

Insider Transactions

Filters

Keyboard Shortcuts: Show (a) | Close (Esc)

People also followed
HAMM ROBERT A

BIOGEN INC.
GILEAD SCIENCES, INC.

Allovir, Inc.
ELI LILLY & Co
VERTEX PHARMACEUTICALS INC / MA

CRISPR Therapeutics AG